Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics

Integra LifeSciences (IART) reported $415.61 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 0.6%. EPS of $0.45 for the same period compares to $0.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $395.64 million, representing a surprise of +5.05%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.43.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Organic Revenue Growth: -1.4% compared to the -6.3% average estimate based on four analysts.Revenue- Codman Specialty Surgical- Total: $303.96 million compared to the $294.18 million average estimate based on four analysts. The reported number represents a change of +0.7% year over year.Revenue- Tissue Technologies- Total: $111.65 million versus $101.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.1% change.Revenue- Tissue Technologies- Wound Reconstruction and Care: $84.75 million compared to the $80.24 million average estimate based on two analysts. The reported number represents a change of -3.4% year over year.Revenue- Tissue Technologies- Private Label: $26.9 million versus the two-analyst average estimate of $25.3 million. The reported number represents a year-over-year change of -6.3%.View all Key Company Metrics for Integra here>>>Shares of Integra have returned -8.5% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks